Mammaglobin-A (23-31)

Mammaglobin-A (23-31) is a synthetic peptide fragment derived from the mammaglobin-A protein, a member of the secretoglobin family predominantly expressed in mammary tissue. As a well-characterized epitope, this peptide represents amino acid residues 23 to 31 of the parent protein, making it a valuable tool for research into peptide-antibody interactions, immunogenicity studies, and biomarker discovery. Its sequence specificity and structural features provide critical insights into the molecular recognition events relevant in breast tissue biology and related pathologies. Given its unique origin and defined sequence, Mammaglobin-A (23-31) has become an important reagent in a variety of biochemical and molecular biology applications, particularly those focused on cancer research and immunological assay development.

Epitope mapping: As a defined peptide segment within the mammaglobin-A protein, the 23-31 region serves as a highly specific tool for epitope mapping studies. Researchers utilize this fragment to identify and characterize antibody binding sites, enabling the development and validation of monoclonal and polyclonal antibodies against mammaglobin-A. Such mapping is essential for understanding immune recognition patterns, which can inform the selection of antibody pairs for use in immunoassays and diagnostic platforms targeting breast tissue markers.

Immunoassay development: The peptide's precise sequence and immunoreactivity make it a suitable standard or capture antigen in the design of enzyme-linked immunosorbent assays (ELISA), western blot protocols, and other immunodetection techniques. By incorporating the 23-31 fragment as a reference or target antigen, assay developers can calibrate and optimize detection systems for mammaglobin-A, improving assay specificity and sensitivity. This capability is particularly valuable in research settings where accurate quantification of breast tissue markers is required.

Biomarker validation: In translational research, the use of this peptide fragment supports the validation of mammaglobin-A as a biomarker for breast tissue characterization and disease monitoring. Synthetic peptides corresponding to immunodominant regions, such as residues 23-31, are employed in comparative studies to assess the presence and abundance of endogenous mammaglobin-A in biological samples. These investigations contribute to the establishment of reliable peptide-based standards for analytical and preclinical studies.

Peptide-antibody interaction studies: The 23-31 fragment is frequently utilized in binding assays to elucidate the molecular basis of antibody recognition. By examining the interaction between this peptide and specific antibodies, researchers can dissect the structural determinants of antigen-antibody affinity and specificity. These studies are instrumental in the rational design of improved detection reagents and can also inform the engineering of antibody derivatives with enhanced performance characteristics.

Peptide synthesis and modification research: As a well-defined peptide, the 23-31 sequence is often used as a model substrate in studies of solid-phase peptide synthesis, post-synthetic modifications, and peptide stability assessments. Its manageable length and established sequence facilitate investigations into synthetic methodologies, peptide labeling, and conjugation strategies. Insights gained from such research can be applied to the development of advanced peptide-based probes and reagents for use in a wide range of biochemical applications.

Through these diverse research applications, the 23-31 fragment of mammaglobin-A demonstrates its utility as a versatile tool in peptide science, immunology, and biomarker studies. Its defined sequence, immunological relevance, and compatibility with a variety of analytical techniques make it an essential reagent for scientists engaged in breast tissue research and the broader field of peptide-based assay development.

1. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

2. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

3. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

4. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

5. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I